GlassScriptPhysician profile
Julia J Irwin
NPI 1306951124
$16,073.73
in general payments reported to CMS, 2019-2025
32 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $1,007 · 2021: $2,412 · 2022: $2,562 · 2023: $2,672 · 2024: $2,970 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,592 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,591.85 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,562.44 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,795.34 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,733.60 | 2021-2025 | |
| Lundbeck LLC | $1,438.36 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,314.57 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,278.23 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $951.38 | 2019-2025 | Trintellix |
| Alkermes, INC. | $803.65 | 2020-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $742.11 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $712.62 | 2019-2025 | Ingrezza |
| Almatica Pharma LLC | $532.71 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $432.30 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $293.76 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $229.60 | 2024-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $214.13 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $192.48 | 2022-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $145.12 | 2020-2022 | |
| Eisai INC. | $136.97 | 2021-2022 | |
| Viiv Healthcare Company | $118.17 | 2021 | |
| Indivior INC. | $65.01 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $62.01 | 2019-2020 | |
| Sage Therapeutics, LLC | $55.10 | 2021 | |
| Allergan, INC. | $42.79 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $40.07 | 2019 | |
| Adlon Therapeutics L.P. | $33.70 | 2019 | |
| Corium, LLC | $31.68 | 2022 | |
| Tonix Medicines, INC. | $31.64 | 2025 | Tonmya |
| Noven Therapeutics, LLC | $30.30 | 2023 | Xelstrym, Secuado |
| Bausch Health US, LLC | $20.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $10.87 | 2019 | |
| Sumitomo Pharma America, INC. | $6.43 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.